RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SAB Biotherapeutics Stock

SAB Biotherapeutics ROA 2024

SAB Biotherapeutics ROA

-0.5

Ticker

SABS

ISIN

US78397T1034

In 2024, SAB Biotherapeutics's return on assets (ROA) was -0.5, a 36.54% increase from the -0.37 ROA in the previous year.

SAB Biotherapeutics Aktienanalyse

What does SAB Biotherapeutics do?

SAB Biotherapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding SAB Biotherapeutics's Return on Assets (ROA)

SAB Biotherapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing SAB Biotherapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider SAB Biotherapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in SAB Biotherapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about SAB Biotherapeutics stock

What is the Return on Assets (ROA) of SAB Biotherapeutics this year?

The Return on Assets (ROA) of SAB Biotherapeutics is -0.5 undefined this year.

What was the ROA of SAB Biotherapeutics compared to the previous year?

The ROA of SAB Biotherapeutics has increased by 36.54% compared to the previous year.

What consequences do high ROA have for investors of SAB Biotherapeutics?

A high ROA is advantageous for investors of SAB Biotherapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in SAB Biotherapeutics?

A low ROA can be unfavorable for investors of SAB Biotherapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of SAB Biotherapeutics affect the company?

An increase in ROA of SAB Biotherapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of SAB Biotherapeutics impact the company?

A reduction in the ROA of SAB Biotherapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of SAB Biotherapeutics?

Some factors that can influence the ROA of SAB Biotherapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of SAB Biotherapeutics important for investors?

The ROA of SAB Biotherapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can SAB Biotherapeutics take to improve ROA?

To improve ROA, SAB Biotherapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does SAB Biotherapeutics pay?

Over the past 12 months, SAB Biotherapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SAB Biotherapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of SAB Biotherapeutics?

The current dividend yield of SAB Biotherapeutics is .

When does SAB Biotherapeutics pay dividends?

SAB Biotherapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SAB Biotherapeutics?

SAB Biotherapeutics paid dividends every year for the past 0 years.

What is the dividend of SAB Biotherapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is SAB Biotherapeutics located?

SAB Biotherapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von SAB Biotherapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SAB Biotherapeutics from 11/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/15/2024.

When did SAB Biotherapeutics pay the last dividend?

The last dividend was paid out on 11/15/2024.

What was the dividend of SAB Biotherapeutics in the year 2023?

In the year 2023, SAB Biotherapeutics distributed 0 USD as dividends.

In which currency does SAB Biotherapeutics pay out the dividend?

The dividends of SAB Biotherapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SAB Biotherapeutics

Our stock analysis for SAB Biotherapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SAB Biotherapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.